EyeGene Balance Sheet Health
Financial Health criteria checks 6/6
EyeGene has a total shareholder equity of ₩56.5B and total debt of ₩3.1B, which brings its debt-to-equity ratio to 5.4%. Its total assets and total liabilities are ₩69.6B and ₩13.1B respectively.
Key information
5.4%
Debt to equity ratio
₩3.07b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩37.26b |
| Equity | ₩56.49b |
| Total liabilities | ₩13.08b |
| Total assets | ₩69.57b |
Financial Position Analysis
Short Term Liabilities: A185490's short term assets (₩38.9B) exceed its short term liabilities (₩5.3B).
Long Term Liabilities: A185490's short term assets (₩38.9B) exceed its long term liabilities (₩7.8B).
Debt to Equity History and Analysis
Debt Level: A185490 has more cash than its total debt.
Reducing Debt: A185490's debt to equity ratio has reduced from 113.3% to 5.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A185490 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A185490 has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 18.2% each year.